Menu Search
Equities

3SBio Inc

1530:HKG

3SBio Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)5.52
  • Today's Change-0.17 / -2.99%
  • Shares traded6.32m
  • 1 Year change-22.91%
  • Beta0.8179
Data delayed at least 15 minutes, as of Nov 22 2024 08:08 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in CNYIncome statement in CNYView more

Year on year 3SBio Inc had net income fall -19.13% from 1.92bn to 1.55bn despite a 13.84% increase in revenues from 6.87bn to 7.82bn.
Gross margin85.94%
Net profit margin20.27%
Operating margin29.67%
Return on assets7.25%
Return on equity11.89%
Return on investment10.26%
More ▼

Cash flow in CNYView more

In 2023, 3SBio Inc increased its cash reserves by 21.35%, or 459.42m. The company earned 2.08bn from its operations for a Cash Flow Margin of 26.65%. In addition the company used 1.35bn on investing activities and also paid 352.98m in financing cash flows.
Cash flow per share0.9074
Price/Cash flow per share6.17
Book value per share6.45
Tangible book value per share3.83
More ▼

Balance sheet in CNYView more

3SBio Inc has a Debt to Total Capital ratio of 19.98%, a lower figure than the previous year's 21.91%.
Current ratio1.72
Quick ratio1.57
Total debt/total equity0.293
Total debt/total capital0.1998
More ▼

Growth rates in CNY

Year on year, growth in earnings per share excluding extraordinary items dropped -16.01%. Additionally, five year annualized earnings per share growth is in-line with the industry average relative to its peers.
EPS growth(5 years)4.96
EPS (TTM) vs
TTM 1 year ago		-10.74
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.